Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced that its management team will participate in a fireside chat and one-on-one meetings at the Cantor 2026 Global Healthcare Conference, scheduled for September 9-11, 2026, in New York. President and CEO Seth Lederman, M.D., will present on September 10 from 3:55 to 4:25 p.m. ET. The presentation will be webcast live and available for replay through the Investors section of the Tonix website.
This announcement comes on the heels of significant progress for the company, which is now a fully-integrated, commercial-stage biotechnology firm focused on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. Tonix's flagship medicine, TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), was recently approved by the FDA as the first new treatment for fibromyalgia in over 15 years. This approval marks a major milestone for the company and patients who have had limited options for managing this chronic condition.
The commercial CNS infrastructure that Tonix has built supports its marketed products, including its acute migraine treatments Zembrace SymTouch and Tosymra. The company is also exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, which could expand its therapeutic reach. Additionally, Tonix's CNS pipeline includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare genetic disorder that often leads to life-threatening obesity.
Beyond CNS, Tonix is advancing a pipeline of immunology programs. These include TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor designed to prevent kidney transplant rejection. These programs highlight the company's commitment to addressing serious conditions with significant unmet needs.
The company's participation in the Cantor conference is an opportunity to engage with the investment community and provide updates on its commercial launch and clinical development activities. Investors and stakeholders can access the live webcast and replay via the company's website. For more details on the conference and Tonix's participation, the full press release is available at https://nnw.fm/hajiz.
Tonix has also established a newsroom where the latest updates and news regarding the company can be found at https://nnw.fm/TNXP. As the company continues to execute on its strategic goals, it remains dedicated to developing and delivering innovative therapies that could make a meaningful difference in patients' lives.
While TONMYA has received approval for fibromyalgia, other product candidates in Tonix's pipeline are investigational drugs or biologics, and their safety and efficacy have not yet been established for any indication. The company's forward-looking statements involve risks and uncertainties, and actual results may differ materially.
